Was appointed as a Director in February 2018, and the CEO and the Chief Scientific Officer in February 2021.

He was re-designated as an executive Director in February 2021. Dr. Li has also held positions at CARsgen Therapeutics. He has been a director and the chief executive officer since October 2014, and the chief scientific officer since December 2017.

Dr. Li has approximately 20 years of work experience in the biopharmaceutical field. Prior to joining our Group, Dr. Li was a project manager at Guilin Pavay Gene Pharmaceutical Co., Ltd. (桂林華諾威基因藥業有限公司) from July 2000 to April 2002. Dr. Li worked at Shanghai Cancer Institute (上海市腫瘤研究所) from July 2005 to June 2018 and served as the leader of the biotherapy research team at the State Key Laboratory of Oncogenes and Related Genes of Shanghai Cancer Institute (上海市腫瘤研究所癌基因及相關基因國家重點實驗室) during such period.

Dr. Li has dedicated himself to developing innovative treatment for the patients with cancer. One of his early career achievements is the identification of GE11, a peptide ligand of EGFR which has become a widely used unnatural peptide in antitumor study now. He is also the inventor of new technologies such as Hpd3cell, a new phage display technology; FR806, a new safety switch for T cell therapy; CycloCAR technology to increase the antitumor activities of chimeric antigen receptor (CAR) T cells. He has a leading role in the research on CAR T cell therapy against solid tumors by publishing the first paper of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide. Dr. Li was a professor Shanghai Cancer Institute, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine (上海交通大學醫學院附屬仁濟醫院上海市腫瘤研究所) and a doctoral supervisor at Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine (上海交通大 學醫學院附屬仁濟醫院).

Dr. Li obtained his bachelor’s degree in preventive medicine and master’s degree in pathology and pathogen biology from the Central South University (中南大學), formerly known as the Hunan Medical University (湖南醫科大學), the PRC, in June 1997 and July 2000 respectively. He obtained his Doctor of Philosophy degree in pathogen biology from Fudan University (復旦大學), the PRC, in June 2005.

Dr. Li was awarded the Leading Talents of Shanghai City (上海市領軍人物) in 2018 and the Shanghai Youth Science and Technology Award (上海市青年科技傑出貢獻獎) in 2019.

Was appointed as a Director in September 2018 and the COO in February 2021. He was re-designated as an executive Director in February 2021.

Dr. Wang has also held positions at other members of our Group. He has been a director and the chief operating officer of CARsgen Therapeutics since October 2014, the general manager of CARsgen Pharmaceuticals since November 2017 and the general manager of CARsgen Diagnostics since November 2020.

Prior to joining our Group, Dr. Wang worked at Zhejiang Academy of Medical Sciences (浙江省醫學科學院) from July 2009 to January 2011, served as the deputy general manager of Shanghai Ruijin Biotechnology Co., Ltd. (上海銳勁生物技術有限公司) from January 2011 to June 2013, and the general manager of YIJIE Biotech (Shanghai) from July 2013 to October 2014.

Dr. Wang obtained his bachelor’s degree in biochemistry from Sichuan University (四川 大學), the PRC, in June 1999. He received his master’s degree and Doctor of Philosophy degree in pathogenic organisms from Fudan University (復旦大學), the PRC, in June 2003 and June 2009, respectively.

Joined the Group in January 2020 and is our Senior Vice President, Global Regulatory Affairs.

Dr. Fan was a laboratory director at The Brooklyn Hospital Center from January 1995 to October 2000. In November 2000 Dr. Fan joined the New York Presbyterian Medical Center as the Lab Manager of the Stem Cell Processing Laboratory. In June 2002, she joined the Memorial Sloan-Kettering Cancer Center. Dr. Fan was a staff scientist at the National Institutes of Health from September 2004 to August 2007. She was a reviewer at the FDA from July 2009 to December 2017 during which she was responsible for reviewing IND applications, BLAs and medical devices.

Dr. Fan obtained her bachelor’s degree in medicine from Beihua Univeristy (北華大學) (previously known as Jilin Medical College (吉林醫學院)) (equivalent to doctor of medicine in the United States) in the PRC in December 1982. Dr. Fan received FDA Outstanding Service Award and CBER Technical Excellence Award while working at the FDA.

Joined our Group in June 2017 and is our Senior Vice President, Business Development.

Dr. Hsu has over 15 years of work experience in business management and strategic planning in the biotechnology industry. Prior to joining our Group, Dr. Hsu served as director of business development at Acadia Pharmaceuticals (NASDAQ: ACAD) and vice president of corporate development and strategy at Lpath, Inc. (NASDAQ: LPTN) between January 2005 and November 2016.

Dr. Hsu obtained his bachelor’s degree in biochemistry and cell biology and his doctorate degree in molecular pathology from the University of California, San Diego in the United States, in June 1993 and June 1999, respectively. He received his master’s degree in business administration from the University of California, Irvine in the United States, in June 2001.

Joined our Group in December 2016 and is our Vice President, Strategic Alliances and Operations.

Dr. Jia has served in CARsgen Therapeutics Corporation, our wholly-owned subsidiary incorporated in the United States since joining our Group, including as the Vice President, Business Development responsible for overseeing the corporate operations of the Group in the United States, leading the strategic alliances and managing CMC operations from December 2016 to July 2017, as the Vice President, Strategic Alliances responsible for overseeing the corporate operations in the United States, leading strategic alliances, managing CMC operations from July 2017 to December 2018, and as the Vice President, Strategic Alliances and Operations responsible for overseeing the corporate operations in the United States, leading strategic alliances, managing CMC operations from January 2019 to present.

Dr. Jia obtained his bachelor’s degree in biochemistry from Sichuan University (四川大 學), the PRC, in July 1999 and his doctorate degree in biochemistry and molecular biology from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (中國科學院 上海生命科學研究院), the PRC, in August 2004. He has been a member of The North American Vascular Biology Organization and Sigma Xi since 2006 and 2008, respectively. In 2014, he joined The Nitric Oxide Society as a member. He became a member of American Association for the Advancement of Science in 2016. Dr. Jia joined the American Society of Clinical Oncology as an allied physician and doctoral scientist in 2017. He has been a member of the American Society of Hematology and a full member of the American Society of Quality since 2019.

Joined our Group in August 2018 and is our Senior Vice President, Clinical Development.

Dr. Ma was the director of clinical operations at Endocyte, Inc. (NASDAQ: ECYT) from June 2012 to July 2014. He then worked as a temporary employee at Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) from September 2014 to December 2014 and served as the director of clinical development from December 2014 to May 2016. Dr. Ma served as the senior medical director at Immatics Biotechnologies GmbH (NASDAQ: IMTX) from May 2016 to August 2018.

Dr. Ma obtained his bachelor’s degree in clinical medicine and his master’s degree in cancer pathophysiology from Central South University (中南大學), formerly known as Hunan Medical University (湖南醫科大學)), the PRC, in July 1994 and July 1997, respectively. He received his master’s degree in business administration from University of Georgia, the United States, in May 2005. Dr. Ma has been a member of the American Society of Clinical Oncology since 2011. He has also been a member of the American Society of Hematology since 2016.

Joined our Group in June 2018 and is our Vice President.

Dr. Wang previously worked at Xiangya Hospital of Central South University (中南大學 湘雅醫院). She also worked at Hangzhou MSD Pharmaceutical Co. Ltd. – Shanghai Branch (杭 州默沙東製藥有限公司 – 上海分公司) from January 2007 to August 2011, where she was responsible for the medical affairs in the medical department. Dr. Wang then served at Beijing Novartis Pharma Co., Ltd. (北京諾華製藥有限公司) as a senior medical scientific expert from September 2011 to May 2012. Prior to joining our Group, Dr. Wang served as the associate safety risk lead and subsequently the clinical program lead at the China R&D center of Pfizer (China) Research and Development Co., Ltd. (輝瑞(中國)研究開發有限公司) from May 2012 to May 2018.

Dr. Wang obtained her bachelor’s degree in clinical medicine from Central South University (中南大學), formerly known as Hunan Medical University (湖南醫科大學), the PRC, in June 1997. She obtained her master’s degree in clinical medicine and doctorate degree in pediatrics from Central South University and Fudan University (復旦大學), the PRC, in June 2003 and July 2007, respectively.

Joined the Group in March, 2021 and is our Senior Vice President, Finance.

Prior to joining our Company, Ms. Xie served as the vice president, finance of Connect Biopharma (Shanghai) Co., Ltd. (康乃德生物醫藥(上海)有限公司), a subsidiary of Connect Biopharma Holdings Limited (NASDAQ: CNTB) from October 2020 to March 2021 during which she was responsible for U.S. listing, finance and tax related matters. Prior to this, Ms. Xie served as the chief financial officer of Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd. (三生國健藥業(上海)股份有限公司) (SSE Sci-Tech Innovation Board: 688336) from April 2019 to May 2020 and she was the vice president and the chief financial officer (China region) of SciClone Pharmaceuticals (China) Co., Ltd. (賽生醫藥(中國)有限公司), a wholly-owned subsidiary of SciClone Pharmaceuticals Holdings Limited (賽生藥業控股有限公司) (HKEX: 6600) from August 2012 to September 2018. From November 2007 to July 2012, Ms. Xie served as the vice president, finance of Shanghai ChemPartner Co., Ltd. (上海睿智化學研究有 限公司). Ms. Xie was a senior manager in PricewaterhouseCoopers Consultants, Shenzhen Co., Ltd. Shanghai Branch from August 2005 to November 2007 and was responsible for corporate mergers and acquisitions and financial due diligence related work.

Ms. Xie obtained her bachelor’s degree in business administration in Boston University in May 1994. She has also earned a master of business administration degree (MBA) in INSEAD in July 2003.